Warmuth Markus Insider Profile
4 Followers
Warmuth Markus, President & CEO, Director at Monte Rosa Therapeutics, holds 585.04K shares in Monte Rosa Therapeutics (Ticker: GLUE). Most recently, Warmuth Markus Sold 9,500 shares of Monte Rosa Therapeutics on Jul 17, 2026 for an estimated value of $220.21K.
Warmuth Markus Monte Rosa Therapeutics (GLUE)President & CEO, Director
Monte Rosa Therapeutics (GLUE)
President & CEO, Director
Ranked #38,321 out of 108,921 Corporate Insiders
Profitable Transactions
2 out of 2 Profitable Transactions
Average Return
+33.80%
Average return per transaction
Time Frame
Compare to
Insider Roles
President & CEO, Director
Roles that Warmuth Markus holds in companies
Most Profitable Insider Trade
The most profitable trade made by Warmuth Markus
Warmuth Markus's Trading History
List of latest transactions for each holding click on a transaction to see Warmuth Markus's performance on stock
You May Also Like
Warmuth Markus insider profile FAQ
What is the percentage of profitable transactions made by Warmuth Markus?
The percentage of profitable transactions made by Warmuth Markus is 100%.
What is the average return per transaction made by Warmuth Markus?
The average return per transaction made by Warmuth Markus is 33.80%.
What stocks does Warmuth Markus hold?
Warmuth Markus holds: GLUE stocks.
What was Warmuth Markus’s latest transaction?
Warmuth Markus latest transaction was an Informative Sell of $220.21K.
What was Warmuth Markus's most profitable transaction?
Warmuth Markus’s most profitable transaction was an Informative Sell of GLUE stock on July 17, 2026. The return on the trade was 43.60%.
What is Warmuth Markus's role in Monte Rosa Therapeutics?
Warmuth Markus's role in Monte Rosa Therapeutics is President & CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.